| 证券代码 | INTS.O |
| 证券名称 | Intensity Therapeutics Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2023-06-30 |
| 首发价格(元) | 5 USD |
| 首发数量(股) | 3900000 |
| 首发募资额(元) | 19,500,000.00 USD |
| 首发主承销商 | Freedom Capital Markets,The Benchmark Company, LLC |
| 货币单位 | USD |
| 公司名称 | Intensity Therapeutics, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 61 Wilton Road, 3rd Floor, Westport, Connecticut, USA |
| 成立日期 | 2012-11-30 |
| 董事会主席 | Lewis H. Bender |
| 公司属地 | United States 美国 |
| 公司网址 | www.intensitytherapeutics.com |
| 电话 | +1 (203) 221-7381 |
| 传真 | - |
| 公司简介 | Intensity Therapeutics, Inc. is a privately held, clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. Intensity leverages its DfuseRx technology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity’s product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. |